Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266244 | 0.86 | TSHR (0.58) | TSHRTDP1KDM4EHPGDALDH1A1 | |
| SCHEMBL12354118 | 0.76 | TSHR (1.00) | TSHRTDP1KDM4EHPGDALDH1A1 | |
| SCHEMBL29478348 | 0.76 | TSHR (0.62) | TSHRTDP1KDM4EHPGDALDH1A1 | |
| SCHEMBL288796 | 0.76 | TSHR (0.62) | TSHRTDP1KDM4EHPGDALDH1A1 | |
| SCHEMBL20885355 | 0.75 | MAPT (0.43) | TSHRKDM4EALDH1A1TP53MAPT | |
| SCHEMBL30337088 | 0.74 | TP53 (0.62) | TSHRTDP1HPGDALDH1A1TP53 | |
| SCHEMBL28972723 | 0.74 | TP53 (0.62) | TSHRTDP1HPGDALDH1A1TP53 | |
| Alcohol SCHEMBL28109153 | 0.73 | TSHR (0.59) | TSHRTDP1KDM4EHPGDALDH1A1 | |
| SCHEMBL9972492 | 0.73 | TSHR (0.61) | TSHRHPGDSMN1; SMN2TP53MAPT | |
| Edetic Acid SCHEMBL8351996 | 0.72 | ALDH1A1 (0.60) | TSHRTDP1KDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157375-A1 | COMPOUND | LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE (GB) | 2013-06-20 | — | — | US | disclosed |
| EP-2564205-A1 | COMPOUND | King's College London (GB) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011135361-A1 | COMPOUND | KING'S COLLEGE LONDON (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-7268164-B2 | Anti-epileptogenic agents | QUEENS UNIVERSITY AT KINGSTON (CA) | 2007-09-11 | — | — | US | disclosed |
| EP-1635909-A2 | TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES | Neurochem (International) Limited (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-19 | — | — | US | disclosed |
| US-6930112-B2 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2005-08-16 | — | — | US | disclosed |
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-17 | — | — | US | disclosed |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-10 | — | — | US | disclosed |
| US-20030229144-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2003-12-11 | — | — | US | disclosed |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | QUEEN'S UNIVERSITY AT KINGSTON AND NEUROCHEM, INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY (CA) | 2003-08-14 | — | — | US | disclosed |
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2002096424-A1 | HETEREOCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002083651-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002073208-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-09-19 | — | — | WO | disclosed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | disclosed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | CA3, GAP43, SLC1A2 | TSHR 3717/4885TDP1 2580/4885KDM4E 2320/4885 |
| US-20030229144-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | TSHR 3667/4885TDP1 2371/4885KDM4E 1626/4885 |
| US-20130157375-A1 | COMPOUND | TFRC, FTH1, SLC40A1 | TSHR 801/4885TDP1 4578/4885KDM4E 3973/4885 |
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | GAP43, GABRE, CA3 | TSHR 4089/4885TDP1 2673/4885KDM4E 2827/4885 |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | SLC1A2, SLC1A1, SLC1A3 | TSHR 4289/4885TDP1 2348/4885KDM4E 1615/4885 |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | APP, IAPP, PSEN1 | TSHR 4543/4885TDP1 1472/4885KDM4E 4537/4885 |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | NUDT1, DPYD, TYMP | TSHR 4639/4885TDP1 154/4885KDM4E 1939/4885 |
| US-20020025949-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | TSHR 3667/4885TDP1 2371/4885KDM4E 1626/4885 |
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | APP, PSEN1, PSEN2 | TSHR 4758/4885TDP1 1574/4885KDM4E 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.